Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:EVI5-GCLM

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: EVI5-GCLM
	FusionPDB ID: 27783
	FusionGDB2.0 ID: 27783
		Hgene	Tgene
	Gene symbol	EVI5	GCLM
	Gene ID	7813	2730
	Gene name	ecotropic viral integration site 5	glutamate-cysteine ligase modifier subunit
	Synonyms	EVI-5\|NB4S	GLCLR
	Cytomap	1p22.1	1p22.1
	Type of gene	protein-coding	protein-coding
	Description	ecotropic viral integration site 5 protein homologdJ846D11.1 (ecotropic viral integration site 5)neuroblastoma stage 4S gene protein	glutamate--cysteine ligase regulatory subunitGCS light chainGSC light chaingamma-ECS regulatory subunitgamma-glutamylcysteine synthetase regulatory subunitglutamate-cysteine ligase (gamma-glutamylcysteine synthetase), regulatory (30.8kD)glutamate-cy
	Modification date	20200313	20200313
	UniProtAcc	Q96CN4 Main function of 5'-partner protein: FUNCTION: Functions as a GTPase-activating protein (GAP) with a broad specificity. {ECO:0000269\|PubMed:16923123}.	P48507 Main function of 5'-partner protein:
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000370331, ENST00000540033, ENST00000543509, ENST00000491940,	ENST00000467772, ENST00000370238,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	15 X 15 X 4=900	4 X 3 X 3=36
	# samples	16	4
	** MAII score	log2(16/900*10)=-2.49185309632967 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Fusion gene context	PubMed: EVI5 [Title/Abstract] AND GCLM [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: EVI5 [Title/Abstract] AND GCLM [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	EVI5(93070864)-GCLM(94367225), # samples:1
Anticipated loss of major functional domain due to fusion event.	EVI5-GCLM seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. EVI5-GCLM seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. EVI5-GCLM seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. EVI5-GCLM seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	EVI5	GO:0043547	positive regulation of GTPase activity	17562788
Tgene	GCLM	GO:0006536	glutamate metabolic process	9841880\|9895302
Tgene	GCLM	GO:0006750	glutathione biosynthetic process	10395918
Tgene	GCLM	GO:0006979	response to oxidative stress	10395918
Tgene	GCLM	GO:0042493	response to drug	9895302

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:93070864/chr1:94367225)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across EVI5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GCLM (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000370331	EVI5	chr1	93070864	-	ENST00000370238	GCLM	chr1	94367225	-	6450	2032	1	2664	887
ENST00000540033	EVI5	chr1	93070864	-	ENST00000370238	GCLM	chr1	94367225	-	6450	2032	1	2664	887
ENST00000543509	EVI5	chr1	93070864	-	ENST00000370238	GCLM	chr1	94367225	-	6473	2055	0	2687	895

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000370331	ENST00000370238	EVI5	chr1	93070864	-	GCLM	chr1	94367225	-	0.000124668	0.9998753
ENST00000540033	ENST00000370238	EVI5	chr1	93070864	-	GCLM	chr1	94367225	-	0.000124668	0.9998753
ENST00000543509	ENST00000370238	EVI5	chr1	93070864	-	GCLM	chr1	94367225	-	0.000135445	0.9998646

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for EVI5-GCLM

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
EVI5	chr1	93070864	GCLM	chr1	94367225	2032	677	AELRQHIAELEIQEFPDVLECTVSHA
EVI5	chr1	93070864	GCLM	chr1	94367225	2055	685	AELRQHIAELEIQEFPDVLECTVSHA

Top

Potential FusionNeoAntigen Information of EVI5-GCLM in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

EVI5-GCLM_93070864_94367225.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B44:03	AELEIQEF	0.9997	0.9685	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B47:01	AELEIQEF	0.9996	0.6683	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:01	AELEIQEF	0.9981	0.9518	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B45:01	AELEIQEFP	0.9948	0.8987	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:02	QEFPDVLEC	0.9924	0.7605	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B45:01	QEFPDVLEC	0.9916	0.9738	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:02	AELEIQEFP	0.9912	0.6932	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:01	IAELEIQEF	0.9803	0.9369	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:08	IAELEIQEF	0.9797	0.8852	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B41:01	AELEIQEFP	0.4843	0.9544	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:01	AELEIQEFP	0.3683	0.7653	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B39:13	QEFPDVLEC	0.3194	0.964	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B41:01	QEFPDVLEC	0.298	0.9602	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:01	QEFPDVLEC	0.2436	0.8787	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B15:18	QHIAELEIQEF	0.9997	0.796	4	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B38:01	QHIAELEIQEF	0.999	0.9876	4	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B38:02	QHIAELEIQEF	0.9986	0.9879	4	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:01	QEFPDVLECTV	0.9959	0.7522	12	23
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B39:08	IQEFPDVL	0.9704	0.8912	11	19
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C05:09	IAELEIQEF	0.9997	0.9668	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C04:10	IAELEIQEF	0.9996	0.8496	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C04:07	IAELEIQEF	0.9996	0.8526	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:15	IAELEIQEF	0.9992	0.9844	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:06	LEIQEFPDV	0.9978	0.6162	9	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:06	QEFPDVLEC	0.995	0.7827	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:06	AELEIQEFP	0.993	0.6487	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:07	IAELEIQEF	0.9886	0.9861	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C04:06	IAELEIQEF	0.965	0.9263	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:14	IAELEIQEF	0.964	0.9819	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:13	IAELEIQEF	0.8705	0.9738	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:04	IAELEIQEF	0.8705	0.9738	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:03	QEFPDVLEC	0.8559	0.5243	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:03	IAELEIQEF	0.5714	0.9894	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B15:31	HIAELEIQEF	0.9813	0.9664	5	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:06	QEFPDVLECTV	0.9993	0.9728	12	23
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B44:10	QEFPDVLECTV	0.9979	0.8023	12	23
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B44:13	AELEIQEF	0.9997	0.9685	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B44:26	AELEIQEF	0.9997	0.9685	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B44:07	AELEIQEF	0.9997	0.9685	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:04	AELEIQEF	0.9992	0.7491	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:07	AELEIQEF	0.9987	0.9295	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:08	AELEIQEF	0.9983	0.9466	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:06	AELEIQEF	0.9983	0.9555	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:05	AELEIQEF	0.9981	0.9518	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:04	AELEIQEF	0.9981	0.958	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:11	AELEIQEF	0.9981	0.9353	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:03	AELEIQEF	0.9969	0.9463	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B48:02	AELEIQEF	0.9597	0.9554	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B41:03	AELEIQEF	0.8584	0.6805	7	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C05:01	IAELEIQEF	0.9997	0.9668	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C04:03	IAELEIQEF	0.9997	0.871	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C04:01	IAELEIQEF	0.9996	0.8526	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:02	IAELEIQEF	0.9992	0.9844	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:02	IAELEIQEF	0.9981	0.9792	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:03	IAELEIQEF	0.9976	0.9914	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:04	IAELEIQEF	0.9976	0.9914	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:11	IAELEIQEF	0.9812	0.9431	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:24	IAELEIQEF	0.9804	0.9675	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:77	IAELEIQEF	0.9803	0.9369	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:04	QEFPDVLEC	0.9788	0.7779	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B35:23	IAELEIQEF	0.9767	0.9344	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C16:01	IAELEIQEF	0.9452	0.9753	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B15:13	IAELEIQEF	0.9384	0.6049	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B57:02	IAELEIQEF	0.9306	0.8407	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C12:02	IAELEIQEF	0.9228	0.9828	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C03:06	IAELEIQEF	0.9121	0.9914	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B53:02	IAELEIQEF	0.9105	0.5757	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B18:11	QEFPDVLEC	0.747	0.9476	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C02:02	IAELEIQEF	0.6997	0.9797	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C02:10	IAELEIQEF	0.6997	0.9797	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-C08:01	IAELEIQEF	0.5714	0.9894	6	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B41:03	QEFPDVLEC	0.4417	0.7738	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:04	AELEIQEFP	0.3683	0.7653	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:05	AELEIQEFP	0.3683	0.7653	7	16
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:04	QEFPDVLEC	0.2436	0.8787	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B50:05	QEFPDVLEC	0.2436	0.8787	12	21
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B15:08	HIAELEIQEF	0.9998	0.9488	5	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:04	LEIQEFPDVL	0.9958	0.7484	9	19
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-A25:01	HIAELEIQEF	0.9922	0.9504	5	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B38:05	QHIAELEIQEF	0.999	0.9876	4	15
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:04	QEFPDVLECTV	0.9979	0.9535	12	23
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	HLA-B40:36	QEFPDVLECTV	0.9955	0.7029	12	23

Top

Potential FusionNeoAntigen Information of EVI5-GCLM in HLA II

EVI5-GCLM_93070864_94367225.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1201	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1201	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1203	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1203	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1205	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1205	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1206	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1206	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1207	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1207	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1210	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1210	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1211	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1211	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1212	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1212	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1213	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1213	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1214	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1214	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1215	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1215	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1217	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1217	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1218	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1218	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1221	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1221	LRQHIAELEIQEFPD	2	17
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1223	RQHIAELEIQEFPDV	3	18
EVI5-GCLM	chr1	93070864	chr1	94367225	2032	DRB1-1223	LRQHIAELEIQEFPD	2	17

Top

Fusion breakpoint peptide structures of EVI5-GCLM

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3573	IAELEIQEFPDVLE	EVI5	GCLM	chr1	93070864	chr1	94367225	2032

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of EVI5-GCLM

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3573	IAELEIQEFPDVLE	-5.52598	-5.63938
HLA-B14:02	3BVN	3573	IAELEIQEFPDVLE	-3.23518	-4.27048
HLA-B52:01	3W39	3573	IAELEIQEFPDVLE	-5.96177	-6.07517
HLA-B52:01	3W39	3573	IAELEIQEFPDVLE	-4.73711	-5.77241
HLA-A11:01	4UQ2	3573	IAELEIQEFPDVLE	-10.9354	-11.0488
HLA-A11:01	4UQ2	3573	IAELEIQEFPDVLE	-8.09068	-9.12598
HLA-A24:02	5HGA	3573	IAELEIQEFPDVLE	-6.42729	-6.54069
HLA-A24:02	5HGA	3573	IAELEIQEFPDVLE	-4.59622	-5.63152
HLA-B27:05	6PYJ	3573	IAELEIQEFPDVLE	-5.20962	-6.24492
HLA-B27:05	6PYJ	3573	IAELEIQEFPDVLE	-3.88034	-3.99374
HLA-B27:03	6PZ5	3573	IAELEIQEFPDVLE	-3.40947	-3.52287
HLA-B27:03	6PZ5	3573	IAELEIQEFPDVLE	-1.86869	-2.90399
HLA-B44:05	3DX8	3573	IAELEIQEFPDVLE	-4.24592	-4.35932
HLA-B44:05	3DX8	3573	IAELEIQEFPDVLE	-3.10496	-4.14026

Top

Vaccine Design for the FusionNeoAntigens of EVI5-GCLM

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
EVI5-GCLM	chr1	93070864	chr1	94367225	11	19	IQEFPDVL	ATCCAGGAGTTTCCAGATGTCTTG
EVI5-GCLM	chr1	93070864	chr1	94367225	12	21	QEFPDVLEC	CAGGAGTTTCCAGATGTCTTGGAATGC
EVI5-GCLM	chr1	93070864	chr1	94367225	12	23	QEFPDVLECTV	CAGGAGTTTCCAGATGTCTTGGAATGCACTGTA
EVI5-GCLM	chr1	93070864	chr1	94367225	4	15	QHIAELEIQEF	CAACACATTGCTGAGCTTGAAATCCAGGAGTTT
EVI5-GCLM	chr1	93070864	chr1	94367225	5	15	HIAELEIQEF	CACATTGCTGAGCTTGAAATCCAGGAGTTT
EVI5-GCLM	chr1	93070864	chr1	94367225	6	15	IAELEIQEF	ATTGCTGAGCTTGAAATCCAGGAGTTT
EVI5-GCLM	chr1	93070864	chr1	94367225	7	15	AELEIQEF	GCTGAGCTTGAAATCCAGGAGTTT
EVI5-GCLM	chr1	93070864	chr1	94367225	7	16	AELEIQEFP	GCTGAGCTTGAAATCCAGGAGTTTCCA
EVI5-GCLM	chr1	93070864	chr1	94367225	9	18	LEIQEFPDV	CTTGAAATCCAGGAGTTTCCAGATGTC
EVI5-GCLM	chr1	93070864	chr1	94367225	9	19	LEIQEFPDVL	CTTGAAATCCAGGAGTTTCCAGATGTCTTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
EVI5-GCLM	chr1	93070864	chr1	94367225	2	17	LRQHIAELEIQEFPD	CTACGACAACACATTGCTGAGCTTGAAATCCAGGAGTTTCCAGAT
EVI5-GCLM	chr1	93070864	chr1	94367225	3	18	RQHIAELEIQEFPDV	CGACAACACATTGCTGAGCTTGAAATCCAGGAGTTTCCAGATGTC

Top

Information of the samples that have these potential fusion neoantigens of EVI5-GCLM

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	EVI5-GCLM	chr1	93070864	ENST00000370331	chr1	94367225	ENST00000370238	TCGA-HU-8238-01A

Top

Potential target of CAR-T therapy development for EVI5-GCLM

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to EVI5-GCLM

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to EVI5-GCLM

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)